Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ancool is a combination oral suspension developed and marketed by Zuventus Healthcare for the management of functional gastrointestinal disorders. It contains four active components: oxetacaine, aluminium hydroxide, magnesium hydroxide, and simethicone. Oxetacaine is a potent local anesthetic that provides rapid symptomatic relief from gastric pain by numbing the stomach lining. Aluminium hydroxide and magnesium hydroxide serve as antacids that neutralize excess gastric acid, while simethicone acts as an antiflatulent by reducing the surface tension of gas bubbles, facilitating their expulsion. The drug is primarily indicated for conditions such as irritable bowel syndrome (IBS), functional dyspepsia, peptic ulcers, and gastroesophageal reflux disease (GERD), addressing symptoms like hyperacidity, flatulence, and smooth muscle spasms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ancool.